Ann: RESPONSE TO ARTICLE IN TODAY'S FAIRFAX M, page-2

re: Ann: RESPONSE TO ARTICLE IN TODAY'S F... Relates to a challenge of the Efexor patent. Efexor is one of the most popular anti-depresents on the market.

Challenging the patent can be part of the process to gain a period exclusivity (I think 6 months) to market the first generic product. It would give Sigma a marketing advantage over other Generic Companies.

This would be a BIG profit earner for Sigma!!!